Question 43252 — pharmacy and medications

Summary

Ms. Danièle Hérin questions the Minister of Solidarity and Health about the reimbursement of preventive treatments for severe migraine. Migraine, a neurological disease affecting several million French people, is sometimes very debilitating for patients, both in their personal and professional lives. In addition, some patients prone to migraine experience therapeutic failure with basic treatments. Very recently, new treatments have appeared in France: anti-CGRP, or monoclonal antibodies targeting CGRP, which are a new class of drugs based on one of the mechanisms of migraine. They allow many patients to return to normal life. To date, these new anti-CGRP treatments are very expensive for patients and are not reimbursed by social security. For the most modest households, pay of the price of his anti-CGRP treatment proves to be a financial burden difficult to bear. Therefore, she would like to know if it could be considered to change the reimbursement system for these anti-CGRP treatments, so that they can be more accessible to patients suffering from severe migraine.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.